Teva Pharmaceutical Industries agreed to acquire Emalex Biosciences in a deal valued at $900 million. The acquisition centers ...
The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often ...
In the first part of his interview, Jeff Golfman, notes how The Strait of Hormuz disruption exposes broader global supply chain contraction, raising risks for vaccines, cancer therapies, and other ...
Rare Pediatric Disease PRVs can accelerate FDA review timelines for another asset, and their resale market creates a tangible ...
In a conversation with Pharmaceutical Executive at Asembia’s AXS26 Summit, Kim Plesnarski, vice president, strategic market ...
In a conversation with Pharmaceutical Executive at Asembia’s AXS26 Summit, Kim Plesnarski, vice president, strategic market ...
VP of commercial strategy and innovation at Innomar, explains how handling uncertainty comes down to discipline. Advertisement. Latest Updated Articles ...
Pharmaceutical Executive: How are US regulatory actions impacting pricing? Dr. Stella Vnook: I'm still trying to reconcile ...
In a conversation with Pharmaceutical Executive, Jeff Golfman, founder and president of Send 123, situates the Strait of ...
In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move ...
At Asembia AXS26, Clarivate’s Dee Chaudhary outlined how U.S. drug pricing policy is rapidly shifting, driving more ...
FDA approves Breztri Aerosphere for asthma, introducing the first single-inhaler triple-combination maintenance therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results